
SCREENING AND TREATMENT FOR BLUNT CEREBROVASCULAR INJURY (BCVI)



Prepared by: MGR, TRAUMA PROGRAM Approved by: MED DIR, TRAUMA

No: 9117



Parent Policy:	Title:	Standard Operating Procedure
None	BCVI Screening & Treatment	Effective Date: 01/25/2021

WHO SHOULD READ THIS PROCEDURE:

This procedure shall be read by WPP Surgery and all practitioners caring for the trauma patient.

SUMMARY:

- I. Screening for BCVI is performed with CTA of the neck according to the Denver criteria.
- II. Antithrombotic therapy deceases the risk of stroke and improves neurologic outcomes.
- III. Follow-up imaging is important, as lesions may improve or worsen over time.

Purpose: Define screening criteria and treatment of BCVI.

Contributing specialties: Trauma surgery, Neurointerventional, Emergency medicine, Radiology

BACKGROUND:

- I. Blunt (non-penetrating) carotid and blunt vertebral artery injuries are collectively referred to as blunt cerebrovascular injuries (BCVI).
- II. BCVI occurs in approximately 1% of patients with blunt trauma admitted to a trauma center. Rates are five-fold higher in patients with severe head, face, and/or cervical spine injuries¹⁻⁴.
- III. The pathologic insult in most cases is an intimal tear. The exposed subendothelial collagen promotes platelet aggregation and thrombus formation, which may occlude the vessel altogether or embolize to the cerebral circulation. In some instances, this process develops into a pseudoaneurysm⁵.
- IV. Early diagnosis and treatment is critical to reducing the risk of stroke and mortality in patients with BCVI⁶⁻⁹.
- V. Screening is performed with CTA of the neck according to the Denver criteria¹⁰.
- VI. Neurologic deficits may not be present on initial exam. Up to half of patients develop neurologic symptoms >12 hours after injury^{11,12}.
- VII. Treatment options include antithrombotic therapy (most common), surgery, and/or endovascular stenting. Antithrombotic therapy deceases the risk of stroke and improves neurologic outcomes¹³⁻²⁰.
- VIII. Follow-up imaging is important, as lesions may improve or worsen over time²¹.

Prepared by:MGR, TRAUMA PROGRAMApproved by:MED DIR, TRAUMA

No: 9117



Printed copies are for reference only. Please refer to the electronic copy for the latest version.

Parent Policy:	Title:	Standard Operating Procedure
None	BCVI Screening & Treatment	Effective Date: 01/25/2021

Denver screening criteria (expanded)²: If operative management is not immediately indicated consider CTA of the neck based on the following criteria.

Denver Criteria		
Signs/symptoms of BCVI		
Potential arterial hemorrhage from neck/nose/mouth		
Cervical bruit in patient <50 y old		
Expanding cervical hematoma		
Focal neurologic defect: TIA, hemiparesis, vertebrobasilar symptoms, Horner's syndrome		
Neurologic deficit inconsistent with head CT		
Stroke on CT or MRI		
Risk factors for BCVI		
High-energy transfer mechanism		
Displaced midface fracture (LeFort II or III)		
Mandible fracture		
Complex skull fracture/basilar skull fracture/occipital condyle fracture		
Severe TBI with GCS <6		
Cervical spine fracture, subluxation, or ligamentous injury at any level		
Near hanging with anoxic brain injury		
Clothesline type injury or seat belt abrasion with significant swelling, pain, or altered mental statu	lS	
TBI with thoracic injuries		
Scalp degloving		
Thoracic vascular injuries		
Blunt cardiac rupture		
Upper rib fractures		

Denver Grading Scale:

- 1. Luminal irregularity or dissection with <25% luminal narrowing
- 2. Dissection or intramural hematoma with >25% luminal narrowing, intraluminal thrombus, or raised intimal flap
- 3. Pseudoaneurysm
- 4. Occlusion
- 5. Transection with free extravasation

Imaging:

- I. All WakeMed CT scans are >16-slice, therefore meeting image quality recommendations.
- II. CTA of the neck is performed in conjunction with CTA of the cervical spine and chest and therefore does not require an additional contrast bolus or radiation exposure.
- III. Ultrasound or MRI imaging of the neck vessels is not recommended as a screening modality.

<u>Consultation</u>: A consult to the "Raleigh-Stroke Neurointerventionalist" team should be placed in Rapid Connect. The neurointerventional team is always available.

<u>Treatment</u>: To be determined in conjunction with the neurointerventional team. Treatment options include:

I. Antithrombotic therapy (anticoagulation or antiplatelet)

Prepared by:MGR, TRAUMA PROGRAMApproved by:MED DIR, TRAUMA

No: 9117



Printed copies are for reference only. Please refer to the electronic copy for the latest version.

Parent Policy:	Title:	Standard Operating Procedure
None	BCVI Screening & Treatment	Effective Date: 01/25/2021

- a. The optimal regimen is not known with respect to antithrombotic agent, duration of treatment, or endpoint of therapy.
- b. Antithrombotic therapy may be limited by associated traumatic injuries.
- c. Antithrombotic options include:
 - i. ASA
 - ii. Plavix
 - iii. Direct oral anticoagulants
 - iv. LMWH
 - v. Heparin infusion
- II. Surgery
 - a. The vast majority of BCVIs occur in surgically inaccessible areas (e.g. skull base or transverse foramen). As such, surgical management is limited to high-grade surgically accessible lesions.
- III. Endovascular stenting
 - b. Endovascular stenting may be considered for grade II and III lesions. However, outcomes may not be improved compared to antithrombotic therapy alone. Contraindications to the immediate/periprocedural use of antithrombotic therapy may preclude stent use.

Follow-up care: To be determined in conjunction with the neurointerventional team.

- I. Follow-up imaging
 - a. There is significant evolution of BCVIs over time. As such, follow-up imaging (CTA or angiography) at or around 7 days post-injury is recommended.
- II. Outpatient follow-up
 - a. All patients should follow up with neurointerventional in 30-90 days.

References:

- 1. Weber CD, Lefering R, Kobbe P, et al. Blunt cerebrovascular artery injury and stroke in severely injured patients: an international multicenter analysis. World J Surg. 2017;30:15.
- 2. Geddes AE, Burlew CC, Wagenaar AE, et al. Expanded screening criteria for blunt cerebrovascular injury: a bigger impact than anticipated. Am J Surg. 2016;212:1167–74.
- 3. Burlew CC, Biffl WL, Moore EE, et al. Blunt cerebrovascular injuries: redefining screening criteria in the era of noninvasive diagnosis. J Trauma Acute Care Surg. 2012;72:330–7.
- 4. Franz RW, Willette PA, Wood MJ, et al. A systematic review and meta-analysis of diagnostic screening criteria for blunt cerebrovascular injuries. J Am Coll Surg. 2012;214:313–27
- 5. Burlew CC, Biffl WL. Blunt cerebrovascular trauma. Curr Opin Crit Care. 2010;16(6):587-595
- 6. Biffl WL, Moore EE, Ryu RK, Offner PJ, Novak Z, Coldwell DM, Franciose RJ, Burch JM. The unrecognized epidemic of blunt carotid arterial injuries: early diagnosis improves neurologic outcome. Ann Surg. 1998;228(4):462–470.
- 7. Miller PR, Fabian TC, Croce MA, et al. Prospective screening for blunt cerebrovascular injuries: analysis of diagnostic modalities and outcomes. Ann Surg. 2002;236(3):386-395.
- Bruns BR, Tesoriero R, Kufera J, Sliker C, Laser A, Scalea TM, Stein DM. Blunt cerebrovascular injuryscreening guidelines: what are we willing to miss? J Trauma Acute Care Surg. 2014;76(3):691– 695.
- 9. Fabian TC, Patton JH Jr., Croce MA, Minard G, Kudsk KA, Pritchard FE. Blunt carotid injury. Importance of early diagnosis and anticoagulant therapy. Ann Surg. 1996;223(5):513–522.

Prepared by: MGR, TRAUMA PROGRAM Approved by: MED DIR, TRAUMA

No: 9117



Printed copies are for reference only. Please refer to the electronic copy for the latest version.

Parent Policy:	Title:	Standard Operating Procedure
None	BCVI Screening & Treatment	Effective Date: 01/25/2021

- 10. Kim DY, Biffl W, Bokhari F, et al. Evaluation and management of blunt cerebrovascular injury: A practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2020; 88:875.
- 11. Burlew CC, Sumislawski JJ, Behnfield CD, et al. Time to stroke: A Western Trauma Association multicenter study of blunt cerebrovascular injuries. J Trauma Acute Care Surg. 2018; 85:858.
- 12. Cothren CC, Biffl WL, Moore EE, et al. Treatment for blunt cerebrovascular injuries: equivalence of anticoagulation and antiplatelet agents. Arch Surg. 2009; 144:685.
- 13. Biffl WL, Moore EE, Ryu RK, et al. The unrecognized epidemic of blunt carotid arterial injuries: early diagnosis improves neurologic outcome. Ann Surg. 1998; 228:462.
- 14. Fabian TC, Patton JH Jr, Croce MA, et al. Blunt carotid injury. Importance of early diagnosis and anticoagulant therapy. Ann Surg. 1996; 223:513.
- 15. Biffl WL, Moore EE, Offner PJ, et al. Blunt carotid arterial injuries: implications of a new grading scale. J Trauma. 1999; 47:845.
- 16. Cothren CC, Moore EE, Biffl WL, et al. Anticoagulation is the gold standard therapy for blunt carotid injuries to reduce stroke rate. Arch Surg. 2004; 139:540.
- 17. Seth R, Obuchowski AM, Zoarski GH. Endovascular repair of traumatic cervical internal carotid artery injuries: a safe and effective treatment option. AJNR Am J Neuroradiol. 2013; 34:1219.
- 18. Hanna K, Douglas M, Asmar S, et al. Treatment of blunt cerebrovascular injuries: Anticoagulants or antiplatelet agents? J Trauma Acute Care Surg. 2020; 89:74.
- 19. McNutt MK, Kale AC, Kitagawa RS, et al. Management of blunt cerebrovascular injury (BCVI) in the multisystem injury patient with contraindications to immediate anti-thrombotic therapy. Injury. 2018; 49:67.
- 20. Burlew CC, Biffl WL, Moore EE, et al. Endovascular stenting is rarely necessary for the management of blunt cerebrovascular injuries. J Am Coll Surg. 2014; 218:1012.
- 21. Biffl WL, Ray CE Jr, Moore EE, et al. Treatment-related outcomes from blunt cerebrovascular injuries: importance of routine follow-up arteriography. Ann Surg. 2002; 235:699.

No: 9117

